Search results: Sage Journals

Open accessReview articleFirst published 2022

Atogepant for the prevention of episodic migraine in adults

Maranda Paige Switzer, Joseph Edward Robinson, Kayla Rena Joyner [...]

Sage Open Medicine

Open accessResearch articleFirst published January, 2022

Time course of efficacy of atogepant for the preventive treatment of migraine: Results from the randomized,double-blind ADVANCE trial

Todd J Schwedt, Richard B Lipton, Jessica Ailani [...]

Cephalalgia

Open accessResearch articleFirst published January, 2024

Pharmacologic characterization of atogepant: A potent and selective calcitonin gene–related peptide receptor antagonist

Eric Moore, Ian M Bell, Mark E Fraley [...]

Cephalalgia

Open accessResearch articleFirst published 2023

Pharmacokinetic and pharmacodynamic assessments of atogepant in healthy male adults: Results from phase 1 studies

Ramesh Boinpally, Marleen Depré, Griet Van Lancker [...]

Cephalalgia Reports

Open accessResearch articleFirst published August, 2025

Long-term safety,efficacy and functional outcomes of atogepant for the preventive treatment of migraine

Sait Ashina, Messoud Ashina, Dagny Holle-Lee [...]

Cephalalgia

Open accessResearch articleFirst published March, 2026

The chronopharmacology of atogepant in migraine prevention: A real-world evaluation of influence of timing of administration on effectiveness and tolerability

Luigi Francesco Iannone, Gabriele Sebastianelli, Federico De Santis [...]

Cephalalgia

Open accessResearch articleFirst published April, 2025

Effectiveness and tolerability of atogepant in the prevention of migraine: A real life,prospective,multicentric study (the STAR study)

Fabrizio Vernieri, Luigi Francesco Iannone, Flavia Lo Castro [...]

Cephalalgia

Open accessResearch articleFirst published September, 2025

Atogepant for the preventive treatment of episodic migraine in Japanese participants: A phase 2/3,randomized,double-blind,placebo-controlled trial with an active treatment extension (RELEASE)

Yasuhiko Matsumori, Hiroshi Yamada, Yoshishige Nagaseki [...]

Cephalalgia

Open accessResearch articleFirst published January, 2023

Safety and tolerability results of atogepant for the preventive treatment of episodic migraine from a 40-week,open-label multicenter extension of the phase 3 ADVANCE trial

Brad C Klein, Rosa Miceli, Lawrence Severt [...]

Cephalalgia

Open accessResearch articleFirst published September, 2023

Patient-reported migraine-specific quality of life,activity impairment and headache impact with once-daily atogepant for preventive treatment of migraine in a randomized,52-week trial

Richard B. Lipton, Rashmi B. Halker Singh, Laszlo Mechtler [...]

Cephalalgia

Open accessReview articleFirst published 2022

Atogepant for the prevention of episodic migraine in adults

Maranda Paige Switzer, Joseph Edward Robinson, Kayla Rena Joyner [...]

Sage Open Medicine

Open accessResearch articleFirst published January, 2022

Time course of efficacy of atogepant for the preventive treatment of migraine: Results from the randomized,double-blind ADVANCE trial

Todd J Schwedt, Richard B Lipton, Jessica Ailani [...]

Cephalalgia

Open accessResearch articleFirst published January, 2024

Pharmacologic characterization of atogepant: A potent and selective calcitonin gene–related peptide receptor antagonist

Eric Moore, Ian M Bell, Mark E Fraley [...]

Cephalalgia

Open accessResearch articleFirst published 2023

Pharmacokinetic and pharmacodynamic assessments of atogepant in healthy male adults: Results from phase 1 studies

Ramesh Boinpally, Marleen Depré, Griet Van Lancker [...]

Cephalalgia Reports

Open accessResearch articleFirst published August, 2025

Long-term safety,efficacy and functional outcomes of atogepant for the preventive treatment of migraine

Sait Ashina, Messoud Ashina, Dagny Holle-Lee [...]

Cephalalgia

Open accessResearch articleFirst published March, 2026

The chronopharmacology of atogepant in migraine prevention: A real-world evaluation of influence of timing of administration on effectiveness and tolerability

Luigi Francesco Iannone, Gabriele Sebastianelli, Federico De Santis [...]

Cephalalgia

Open accessResearch articleFirst published April, 2025

Effectiveness and tolerability of atogepant in the prevention of migraine: A real life,prospective,multicentric study (the STAR study)

Fabrizio Vernieri, Luigi Francesco Iannone, Flavia Lo Castro [...]

Cephalalgia

Open accessResearch articleFirst published September, 2025

Atogepant for the preventive treatment of episodic migraine in Japanese participants: A phase 2/3,randomized,double-blind,placebo-controlled trial with an active treatment extension (RELEASE)

Yasuhiko Matsumori, Hiroshi Yamada, Yoshishige Nagaseki [...]

Cephalalgia

Open accessResearch articleFirst published January, 2023

Safety and tolerability results of atogepant for the preventive treatment of episodic migraine from a 40-week,open-label multicenter extension of the phase 3 ADVANCE trial

Brad C Klein, Rosa Miceli, Lawrence Severt [...]

Cephalalgia

Open accessResearch articleFirst published September, 2023

Patient-reported migraine-specific quality of life,activity impairment and headache impact with once-daily atogepant for preventive treatment of migraine in a randomized,52-week trial

Richard B. Lipton, Rashmi B. Halker Singh, Laszlo Mechtler [...]

Cephalalgia